dc.contributor.author | Dibekoglu, Cengiz | |
dc.contributor.author | Erbas, Oytun | |
dc.date.accessioned | 2022-11-04T19:55:34Z | |
dc.date.available | 2022-11-04T19:55:34Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0102-8650 | |
dc.identifier.issn | 1678-2674 | |
dc.identifier.uri | https://doi.org/10.1590/acb370503 | |
dc.identifier.uri | http://hdl.handle.net/11446/4567 | |
dc.description.abstract | Purpose: To investigate the effect of givinostat treatment in acetic acid-induced ulcerative colitis model in rats. Methods: Thirty male Wistar albino rats were used. Rats were randomly divided into three equal groups, and colitis was induced on 20 rats by rectal administration of %4 solutions of acetic acid. Twenty rats with colitis were randomly divided into two groups. %0.9 NaCl (saline) solution was administered intraperitoneally to the first group of rats (saline group, n=10) at the dose of 1 mL/kg/day. Givinostat was administered intraperitoneally to the second group rats (Givinostat group, n=10) at the dose of 5 mg/kg/day. Samples were collected for biochemical analysis. Colon was removed for histopathological and biochemical examinations. Results: Plasma tumor necrosis factor-alpha (TNF-alpha), pentraxin-3 (PTX-3), and malondialdehyde levels were significantly decreased in the givinostat group compared to the saline group (p<0.05, p<0.001, and p<0.001 respectively; p<0.001, p<0.001, and p<0.001, respectively). Colon TNF-alpha and prostaglandin F2 alpha (PGF-2) levels were significantly decreased (p<0.05, and p<0.001, respectively). The givinostat group had a significantly lower histologic score than saline group (p<0.001, and p<0.001, respectively). Conclusion: Givinostat, a good protector and regenerator of tissue and an anti-inflammatory agent, may be involved in the treatment of colitis in the future. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Acta Cirurgica Brasileira | en_US |
dc.relation.ispartof | Acta Cirurgica Brasileira | en_US |
dc.identifier.doi | 10.1590/acb370503 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Colitis | en_US |
dc.subject | Tumor Necrosis Factor-Alpha | en_US |
dc.subject | Rats | en_US |
dc.subject | Ulcerative-Colitis | en_US |
dc.subject | Oxidative Stress | en_US |
dc.subject | Barrier Function | en_US |
dc.subject | Protein | en_US |
dc.subject | Gastroenterology | en_US |
dc.subject | Pathogenesis | en_US |
dc.subject | Inflammation | en_US |
dc.subject | Activation | en_US |
dc.subject | Disease | en_US |
dc.subject | Targets | en_US |
dc.title | Histone deacetylase inhibitor givinostat has ameliorative effect in the colitis model | en_US |
dc.type | article | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.volume | 37 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Dibekoglu, Cengiz] Istanbul Florence Nightingale Hosp, Dept Gen Surg, Istanbul, Turkey; [Erbas, Oytun] Demiroglu Bilim Univ, Fac Med, Dept Physiol, Istanbul, Turkey; [Dibekoglu, Cengiz; Erbas, Oytun] Demiroglu Bilim Univ, Expt Med Lab, Tubitak Gebze Campus, Kocaeli, Turkey | en_US |
dc.authorid | Dibekoglu, Cengiz/0000-0001-7124-4385 | |
dc.identifier.pmid | 35894303 | en_US |
dc.identifier.scopus | 2-s2.0-85134694702 | en_US |
dc.identifier.wos | WOS:000836182200001 | en_US |
dc.authorscopusid | 6505797608 | |
dc.authorscopusid | 55469991100 | |